Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Add-on fesoterodine for overactive bladder symptoms in men on alpha-blocker therapy
2007-004555-11Phase 4Completed
- Sponsor
- Pfizer
- Start
- Oct 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in overactive bladder (OAB) comparing Fesoterodine add-on with Placebo add-on (2 arms). Primary endpoint: Change in urgency episodes per 24 hours. Started Oct 2007; status: completed.
02
Drugs
fesoterodine
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on 2007-004555-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004555-11.